Business Valuation: Medical Laboratory Equipment

The COVID-19 pandemic exposed critical gaps in global diagnostic infrastructure, triggering an unprecedented wave of laboratory investment that continues to reshape the sector. Governments and healthcare systems worldwide have committed to expanding PCR capacity, biosafety level-3 laboratories, and automated sample processing infrastructure. Swiss companies have been primary beneficiaries: Roche Diagnostics saw its molecular diagnostics division surge during the pandemic and continues to benefit from sustained PCR and antigen testing demand. Tecan's automated liquid handling platforms became essential for high-throughput COVID testing, and the company reported record order intake in 2022-2023. Hamilton Company's precision pipetting robots were deployed across thousands of testing laboratories globally. The investment wave has now broadened beyond COVID into general laboratory modernization, with hospitals and reference labs upgrading aging equipment to automated, connected platforms.

The shift toward precision medicine is fundamentally transforming laboratory diagnostics, creating strong tailwinds for Swiss companies. Companion diagnostics — tests that identify whether a patient will respond to a specific targeted therapy — have become mandatory for an increasing number of oncology drugs. Roche Diagnostics is the undisputed leader in this space, with its cobas platform providing companion diagnostic tests for dozens of targeted cancer therapies, including its own pharma division's drugs (Herceptin, Avastin, Tecentriq). BÜHLMANN Laboratories (Schönenbuch BL) has carved a niche in fecal biomarker diagnostics with its CALEX system, widely used in gastroenterology. The global companion diagnostics market is projected to grow at 12-15% annually through 2030, driven by new biomarker discoveries and regulatory requirements for personalized therapy selection.

Chronic labor shortages in clinical laboratories worldwide are accelerating the adoption of automation and robotics, a segment where Swiss companies hold commanding market positions. Tecan's Fluent and Freedom EVO platforms are industry standards for automated liquid handling in drug discovery, genomics, and clinical diagnostics. Hamilton Company's STAR and Vantage systems offer unmatched precision in nanoliter-range dispensing. The trend extends beyond simple sample preparation to total laboratory automation (TLA), where pre-analytical, analytical, and post-analytical processes are integrated into continuous workflow systems. Roche's cobas connection modules exemplify this approach. Infors HT (Bottmingen BL) contributes to upstream bioprocess automation with its bioreactor and shaker systems used in pharmaceutical and biotech R&D laboratories. The global laboratory automation market is growing at 7-9% annually.

Artificial intelligence is rapidly transforming laboratory diagnostics, with Swiss companies and research institutions playing leading roles. Digital pathology — the scanning of tissue slides into high-resolution digital images for AI-assisted analysis — is one of the fastest-growing segments. Roche's NAVIFY Digital Pathology platform integrates AI algorithms for tumor identification and classification. Swiss AI research, particularly at ETH Zürich and EPFL, is producing breakthrough algorithms in medical image analysis, genomic interpretation, and predictive diagnostics. The convergence of AI with next-generation sequencing (NGS) is enabling liquid biopsies — blood-based cancer detection tests — that promise to revolutionize early cancer screening. Regulatory frameworks for AI-based in-vitro diagnostics are evolving under EU IVDR, with Swissmedic working to establish clear pathways for Software as a Medical Device (SaMD) approvals.

The decentralization of diagnostics from central reference laboratories to point-of-care settings — clinics, pharmacies, emergency rooms, and even patients' homes — represents a structural shift in the laboratory equipment market. Miniaturized, cartridge-based diagnostic instruments are enabling rapid testing for infectious diseases, cardiac markers, blood gases, and coagulation parameters without the need for a centralized laboratory. Swiss precision engineering is ideally suited to develop these miniaturized, high-accuracy systems. The global POCT market is projected to reach USD 50 billion by 2028, growing at 8-10% annually. Swiss companies are well-positioned through Roche's cobas Liat system (rapid molecular testing), Mettler-Toledo's precision measurement technologies for POCT calibration, and numerous startups emerging from ETH and EPFL developing novel biosensor platforms.

The EU In-Vitro Diagnostic Regulation (IVDR), which became fully applicable in May 2022, has fundamentally reshaped the regulatory landscape for diagnostic manufacturers. The IVDR reclassified approximately 85% of IVD devices into higher risk categories, requiring clinical performance studies, more rigorous conformity assessments, and post-market surveillance. For Swiss manufacturers, navigating the IVDR is both a significant compliance burden and a competitive advantage: larger firms like Roche Diagnostics have the regulatory infrastructure to manage the transition, while smaller competitors struggle with the 40-60% increase in certification costs. The shortage of EU Notified Bodies qualified for IVDR assessments has created 12-24 month backlogs, particularly for Class D (highest risk) diagnostics. Swiss companies that achieve early IVDR certification gain significant first-mover advantages in the European market.